Increased levels of PEA-15 were observed in glioblastoma, lymphocytes of patients with B-cell chronic lymphocytic leukaemia and in tumours of NSCLC patients; all of which are resistant to TRAIL (Eramo et al., 2005, Garofalo et al., 2007, Zanca et al., 2008). Here, PEA15 is linked to glioblastoma.